Maxim Group analyst Jason McCarthy maintained a Buy rating on Intec Pharma Ltd (NTEC) yesterday and set a price target of $12. The company’s shares closed yesterday at $6.10.
McCarthy said:
“Intec announced the last patient visit in the P3 ACCORDANCE trial evaluating Accordion Pill Carbidopa/Levodopa (AP-CD/LD) vs. Sinemet (immediate release CD/LD) in Parkinson’s disease (PD). Data is expected in the July/ August timeframe.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.9% and a 29.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intec Pharma Ltd with a $14.33 average price target, a 134.9% upside from current levels. In a report released yesterday, Ladenburg also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.25 and a one-year low of $3.55. Currently, Intec Pharma Ltd has an average volume of 274K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
